STAT

JUNE 3, 2024

It’s been one year since the U.S. surgeon general issued a national warning about an epidemic of loneliness. Other countries recognized the problem earlier: the United Kingdom appointed a minister for loneliness in 2018; Japan did the same in 2021. These initiatives have brought attention to — and spurred action around — an important problem with serious health consequences, which include increased risks of heart disease, dementia, and premature death.

327

327

PharmaVoice

JUNE 3, 2024

Cancer vaccines are taking off in the clinic, and a partnership between Merck and Moderna is at the forefront of a new wave of immunotherapy.

Vaccines 147

Vaccines 147

STAT

JUNE 3, 2024

Paul Marchetti, the head of insurer Elevance Health’s pharmacy benefit manager, has left the company amid a wave of consumer complaints about patients receiving incorrect medicines or being unable to get their prescriptions filled. Elevance did not confirm Marchetti’s departure as the president of CarelonRx, but according to his Linkedin profile, he left the company in May.

Prescription Filling 324

Prescription Filling 324

PharmaVoice

JUNE 3, 2024

Jim Lang, CEO of Eversana, explains the shifting commercial environment and how past drug launch failures are informing the future.

147

147

Speaker: Joe Sharpe and James Carlson

In the world of small business management, the challenge of managing payroll & HR efficiently while scaling operations can be overwhelming. Yet, with the right strategies in place, these challenges can become opportunities for growth and innovation. In this session, Joe Sharpe, Senior Director of Managed Payroll Services at IRIS, will reveal practical methods and expert insights for outsourcing and streamlining payroll processes, resulting in substantial time and resource savings.

STAT

JUNE 3, 2024

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

322

322

PharmaVoice

JUNE 3, 2024

With the billion-dollar-plus deals under its belt with Gilead and Takeda, the biotech’s CEO explains where the company is going next.

130

130

pharmaphorum

JUNE 3, 2024

Understanding the challenges and opportunities in transitioning to IVDR for pharmacogenomics can be complex. Learn more about how to overcome these challenges effectively.

120

120

STAT

JUNE 3, 2024

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith , is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

311

311

EMCrit Project

JUNE 3, 2024

Today, we talk about a paper that showed impressive neurologically intact survival for all-rhythms presenting in cardiac arrest, both OHCA and IHCA. It uses a new set of strategies and technologies called CARL. The Paper Treatment of Refractory Cardiac Arrest by Controlled Reperfusion of the Whole Body: A Multicenter, Prospective Observational Study Supplemental Material […] EMCrit Project by Scott Weingart, MD FCCM.

117

117

STAT

JUNE 3, 2024

More than a year ago, Kaiser Permanente made waves when it said it was creating a new, sprawling entity of nonprofit hospitals and doctors with Geisinger as its first takeover — the latest example of health care companies bulking up in an already highly consolidated industry. Nothing has happened since then, at least publicly. Geisinger’s 10 hospitals and 1,700 employed physicians are now officially part of the group, known as Risant Health.

Hospitals 302

Hospitals Health Insurance Companies 302

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

BioPharma Dive

JUNE 3, 2024

Shares in the company soared by more than 50% as study data showed the pill led to similar levels of weight loss as a rival drug being developed by Eli Lilly.

120

120

STAT

JUNE 3, 2024

In today’s labor market, good help is hard to find. For companies developing antibiotics, it’s becoming nearly impossible. Three years ago, I became CEO of the AMR Action Fund , which is investing approximately $1 billion in biotech companies developing treatments for antimicrobial-resistant infections, a growing global health crisis that now contributes to 4.9 million deaths every year.

281

281

BioPharma Dive

JUNE 3, 2024

The number of oral cancer medications is increasing, opening new possibilities for improved convenience, but some studies show much lower adherence rates with oral oncolytics.

104

104

STAT

JUNE 3, 2024

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading. In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

279

279

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

BioPharma Dive

JUNE 3, 2024

Liquid biopsy has emerged as a revolutionary tool for clinical trials, offering cellular and cell-free methods that provide valuable insights into disease progression and treatment response.

103

103

STAT

JUNE 3, 2024

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month. Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

263

263

The Pharmacist

JUNE 3, 2024

The technology that allows pharmacists to view summary care records changes to a new service from today. The Summary Care Record application (SCRa) will be fully switched off and replaced by the National Care Record Service (NCRS), which provides access to more than 63 million records. Users will automatically be redirected to NCRS, according to NHS England.

99

99

STAT

JUNE 3, 2024

Becton Dickinson plans to pay $4.2 billion for Edwards Lifesciences’ critical care business, which sells technology that monitors the heart conditions of critically ill patients. Edwards had told investors in December 2023 that it planned to spin off the business in order to focus more sharply on addressing structural defects in the heart. BD, meanwhile, wants to increase its monitoring presence in hospitals.

Hospitals 260

Hospitals 260

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

European Pharmaceutical Review

JUNE 3, 2024

A report by Spherical Insights has predicted that the process spectroscopy market will value $35.8 billion by 2033. Process spectroscopy is becoming more connected to automation and digitalisation initiatives, like Industry 4.0, the report stated. The analytical technique can therefore aid smart production and predictive maintenance. Furthermore, incorporating data analytics and artificial intelligence (AI) facilitates predictive process control and optimisation, the report explained.

Pharmaceutical Manufacturing 97

Pharmaceutical Manufacturing Pharmaceutical Companies Pharmaceutical Companies 97

STAT

JUNE 3, 2024

S TAT is putting together a list of books and podcasts that deal with health, medicine, and the life sciences that would be great to check out this summer. We invite our readers to fill out the form below, and you may see your pick in our upcoming annual roundup. To get a little inspiration, check out our past lists from 2023 , 2022 , and 2021.

258

258

Express Pharma

JUNE 3, 2024

Bionova Scientific aims to offer pDNA development services and production of research grade and high quality pDNA Bionova Scientific, an Asahi Kasei Group company, recently announced plans to invest $100 million to expand into plasmid DNA (pDNA) production. The centerpiece of the project is a new 100,000 sq. ft. development and manufacturing facility in The Woodlands, Texas (near Houston).

95

95

STAT

JUNE 3, 2024

Agios Pharmaceuticals said Monday that its drug called mitapivat reduced the need for blood transfusions in patients with a severe form of beta-thalassemia, an inherited blood disorder. The results achieved the primary goal of a placebo-controlled Phase 3 clinical trial, and if the drug is eventually cleared by regulators, could accelerate sales. In the study, 30% of participants responded to treatment with mitapivat compared to 12% of participants offered a placebo.

255

255

pharmaphorum

JUNE 3, 2024

GSK planning to refile anti-BCMA drug Blenrep in the US for multiple myeloma after reporting positive results from the DREAMM-8 trial at ASCO

107

107

STAT

JUNE 3, 2024

A leading contract research organization has agreed to pay $35 million — including the largest-ever fine for violating the Animal Welfare Act — as part of a criminal plea for badly neglecting hundreds of beagles in a breeding facility. The investigation into Inotiv, which provides drug discovery and development services to the pharmaceutical industry, drew national attention in May 2022 after U.S.

249

249

pharmaphorum

JUNE 3, 2024

The BIOSECURE Act is a proposed legislation that reflects the current strained US-Chinese relations, impacting biotech cooperation. Learn more about the implications and challenges.

94

94

STAT

JUNE 3, 2024

You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox every Monday. What’s next for Risant? Kaiser Permanente grabbed everyone’s attention last year when it said it was creating Risant Health, a new and vague entity that acquired Geisinger and had plans to scoop up at least four more health systems that are focused on “value-based care.

Hospitals 246

Hospitals 246

The Pharmacist

JUNE 3, 2024

The Conservative Party has pledged to expand Pharmacy First to include more conditions, as well as have pharmacies provide more contraceptive options and menopause support, if elected at the next general election. The expansion would double the number of GP appointments saved by the scheme and would be funded by cutting the number of NHS […] The post Conservatives pledge to expand Pharmacy First to include acne and chest infections appeared first on The Pharmacist.

93

93

STAT

JUNE 3, 2024

You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting.   Sign up for the last day here. ASCO is more than half done. There is free coffee on the exhibit floor. One booth barista said their team had made 1,400 espressos in a day. Everyone’s perspective is alternating between two verses from Smashing Pumpkins, who are, lest you forget, a Chicago band.

240

240

pharmaphorum

JUNE 3, 2024

Join us for live coverage of BIO 2024, featuring Viola Davis and Brooke Baldwin on Day 1. Stay tuned for exclusive updates and highlights from the event.

101

101

STAT

JUNE 3, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning! It’s an ASCO-full newsletter today (and be sure to peruse the More Reads for more reads) but there’s so much more this week. We’re previewing tomorrow’s advisory committee on the closely watched MDMA therapy from Lykos Therapeutics, and both Jonathan Wosen and I will be at BIO!

Drug Pricing 227

Drug Pricing Drug Development Vaccines 227

Express Pharma

JUNE 3, 2024

The one-day conference to discuss the latest advancements and trends in the field of purification chromatography, essential for professionals in the pharmaceutical, biotechnology, and chemical industries PURIFY’24 West, the fifth edition of PURIFY conferences, Asia’s only chromatography purification conclave, is taking place on June 12, 2024, at ITC Maratha, Mumbai.

92

92

STAT

JUNE 3, 2024

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online meetings and deadlines has predictably returned. But you knew this would happen, yes? After all, the world, such as it is, continues to spin. So time to give it a nudge in a better direction with a cup or three of stimulation.

217

217

Express Pharma

JUNE 3, 2024

The generic equivalent of Prevymis, will be manufactured at Lupin’s Nagpur facility in India Lupin has announced that it has received a tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Letermovir Tablets, 240 mg and 480 mg, to market a generic equivalent of Prevymis Tablets, 240 mg and 480 mg, of Merck Sharp & Dohme.

91

91